This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
a biomarker-guided predictive care company, has presented data showing its FDA-cleared, non-invasive, biomarker-based technology for remote heartfailure monitoring detected twice as many heartfailure events as compared to the weight-based standard of care. Bodyport Inc., Image courtesy: Bodyport Inc.
recently announced that Digitiva, a non-invasive digital health solution for heartfailure management, has been listed with the U.S. a smartphone app designed for heartfailure patients and built on the Welldoc, Inc. a smartphone app designed for heartfailure patients and built on the Welldoc, Inc.
Remote patient monitoring in heartfailure (HF). Abstract Aims Methods of non-invasive remote patient monitoring (RPM) for heartfailure (HF) remain diverse. Modernizing RPM with advanced technologies like non-invasive sensors, artificial intelligence, and cardiac telerehabilitation could enhance its potential.
Genesis is the latest advancement in Robotic Magnetic Navigation technology. Tens of millions of individuals worldwide suffer from arrhythmias – abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern.
We look forward to bringing our AI technology to meet patients and physicians where they are, ultimately benefiting both worldwide.” The companies will also work together to validate the clinical utility of the integrated solution and seek regulatory clearance to bring this technology to market. Under the agreement, InfoBionic.Ai
The robotic technology represented an entirely novel way to address heart rhythm disorders in a minimally invasive procedure with the benefits of robotic precision and safety. When left untreated, arrhythmias may significantly increase the risk of stroke, heartfailure, and sudden cardiac arrest.
Such technology could make it faster and cheaper to evaluate new treatments and, ultimately, help bring successful ones to patients. Generative Artificial Intelligence (Gen AI) can rapidly and accurately screen patients for clinical trial eligibility, according to a new study from Mass General Brigham researchers.
Henry Ford Health's Center for Structural Heart Disease team delivered its first in Michigan FDA-approved VOQUE Transcatheter Tricuspid Valve Replacement System to a heartfailure patient on February 13, 2024 at Henry Ford Hospital in Detroit. Other symptoms include swelling in the abdomen, legs or neck veins.
Caristo Diagnostics Limited has announced the results of a landmark clinical study published in The Lancet that support the ability of Caristo's CaRi-Heart AI technology to quantify coronary artery inflammation and accurately predict cardiac events. The CaRi-Hearttechnology is in clinical use in the UK, European Union, and Australia.
FIRE1s Norm heartfailure management system offers a unique approach for patients to manage heartfailure. The company also announced Ellie McGuire, Partner at Polaris Partners, and Michael Wasserman, Partner and COO at Elevage Medical Technologies have joined its Board of Directors.
This article reviews the use of digital wearable technologies for monitoring of three common cardiovascular conditions: hypertension, heartfailure, and atrial fibrillation.
IntroductionVentricular assist devices (VADs) are lifesavers for people with advanced heartfailure. The design of these devices has undergone drastic changes over time with the latest designs being far more efficient, small, lightweight, and more user-friendly. Top countries include the USA, China, and Germany.
Luigi Caliendo explains the benefits of Robotic Technology to President Vincenzo de Luca. Luigi Caliendo explains the benefits of Robotic Technology to President Vincenzo de Luca. When left untreated, arrhythmias may significantly increase the risk of stroke , heartfailure , and sudden cardiac arrest.
(MedPage Today) -- CHICAGO -- Champions of tricuspid transcatheter edge-to-edge repair (TEER) were buoyed by 2-year results of the TRILUMINATE trial marking the first report of reduced heartfailure (HF) hospitalization for this technology.
The retrospective analysis of data from the MODERATO II study demonstrated that AVIM therapy significantly improved echocardiographic (Echo) markers of diastolic dysfunction, an important component in the development of heartfailure, in hypertensive patients. Advanced HeartFailure Cardiologist, Duke Health on Feb.
mtaschetta-millane Tue, 07/16/2024 - 09:47 July 16, 2024 — Ultrahuman, a pioneer in wearable technology , launches PowerPlugs, a platform for individual apps and plugins built on top of Ultrahuman’s health and wellness data stack. AFib is the most common type of irregular heart rhythm or arrhythmia.
Edwards Lifesciences is going all-in on structural heart and heartfailure, acquiring aortic valve-maker JenaValve Technology and implantable heartfailure monitor company Endotronix for $1.2B and up to $445M in milestone payments.
This irregular heartbeat is associated with increased risks of heartfailure, dementia and stroke. These results pave the way for integration into wearable technologies, allowing early interventions and better patient outcomes. It gives early warnings on average 30 minutes before onset, with an accuracy of around 80%.
American College of Cardiology (ACC) and American Heart Association (AHA) Issue New Hypertrophic Cardiomyopathy (HCM) Management Guidelines 2. New Study Published in JACC: HeartFailure Reveals that Despite Significant Efforts to Improve Acute HeartFailure Treatment Over the Past 20 Years, Management Remains Unchanged 3.
Efforts to foster both intrinsic and extrinsic regenerative responses in heartfailure have once again brought iPS cell technologies to the forefront, thanks to their flexibility in reconstructing tissues in vitro and enabling researchers to investigate the biological mechanisms driving cell-fate decisions.
Research Highlights: Analyzing a patient’s voice recorded daily on a smartphone, artificial intelligence technology detected increasing fluid in their lungs — a sign of worsening heartfailure. In the trial of more than 400 adults with heartfailure.
The global health challenge posed by cardiac arrhythmias, particularly atrial fibrillation (AF), is significant, with heightened risks of stroke, heartfailure, and systemic embolism1. Traditional arrhythmia detection has often missed transient or asymptomatic episodes, relying on symptomatic presentations and episodic monitoring.
ObjectivesTelenursing in cardiac care leverages technology to support self-care and optimize outcomes for heartfailure patients during and beyond the pandemic.
12, 2024 Physicians have a new treatment option for many of the sickest pediatric patients with heartfailure andcardiogenic shock. and Impella CP enable heart recovery as part of the world's smallest heart pump platform. with SmartAssist tim.hodson Wed, 12/18/2024 - 14:06 Dec.
We now have one more technology, on the verge of approval by the FDA. Final message WiSE CRT uses some revolutionary technology and it is a welcome addition in few eligible patients. However, advanced heartfailure therapy never means it can be achieved only by state-of-the-art technology. Reference 1. 2024.2050 2.
Bodyport Presents Preliminary Analysis of SCALE-HF 1 Study on Remote HeartFailure Monitoring at Technology and HeartFailure Therapeutics (THT) Conference 9. FDA Announces Abbott Recall of HeartMate Touch Communication System for Unintentional Pump Start and Stop 8.
mtaschetta-millane Thu, 07/11/2024 - 10:53 July 11, 2024 — Heart Test Laboratories, Inc. Heartfailure (HF) is a growing worldwide public health issue affecting 64 million people annually 1 and is associated with high mortality, lower quality of life and reduced physical capacity while placing substantial costs on the healthcare system.
Early Feasibility Study (FUTURE-HF2) of its FIRE1 System for remote heartfailure monitoring. The FIRE1 System is the first device designed to directly measure a patient’s volume status by measuring the largest vein in the body where most fluid is stored – the inferior vena cava (IVC) – to better manage heartfailure.
Early detection and intervention are essential in addressing cardiovascular diseases, and Eko is dedicated to providing accessible and scalable technologies that empower healthcare providers while improving patient care globally."
Multidisciplinary experts in heartfailure care from across the UK and wider afield gathered for the recent 26th British Society of HeartFailure (BSH) annual meeting. Dr Aaron Henry reports highlights from the meeting.
Atrial fibrillation (AF) significantly increases the risk of stroke and heartfailure, but is frequently asymptomatic and intermittent; therefore, its timely diagnosis poses challenges. Early detection in selected patients may aid in stroke prevention and mitigate structural heart complications through prompt intervention.
Heartfailure (HF) is a prevalent and complex condition that demands precise and efficient management. Furthermore, we investigate the technology and systems in place to aid staff in this endeavour.
Food and Drug Administration ( FDA ) granted an Investigational Device Exemption (IDE) to initiate a US Pivotal Study with its technology. Over 100 patients have been treated with the HighLife technology within different clinical programs in the USA, Europe and APAC. Javits Convention Center, North.
He will guide comprehensive medical education, outreach and guideline integration initiatives to establish Barostim as the standard of care for patients with heartfailure. Dr. Adamson joins CVRx from Abbott Laboratories , where he served as Divisional Vice President and Chief Medical Officer of the HeartFailure division.
"Tricuspid regurgitation can put added strain on the heart and lead to other cardiovascular issues, which can significantly worsen a person's quality of life, but historically there have been few treatment options," said Lars Søndergaard , M.D.,
a medical technology company focused on transforming cardiac care through the power of personalized insights, announced significant developments for the use of artificial intelligence (AI) applied to its proprietary vectorelectrocardiography (VECG) technology, including the addition of new leadership and advisory roles.
Cardiac amyloidosis is a heterogeneous disease that results from the accumulation of abnormal proteins within the heart, impairing its ability to pump blood. Over time, the build-up of these proteins causes the heart muscle to stiffen, eventually leading to heartfailure, which can have dire outcomes if not found early.
Yet an ongoing challenge is how to expand this opportunity to all patients who need a heart in our current setting of limited resources. Transplantation is lifesaving for many of our patients.
The present invention relates to medical methods for transseptal access to the heart using steerable introducers based on the Company’s Morph DNA technology. mtaschetta-millane Wed, 07/17/2024 - 11:06 July 17, 2024 — BioCardia, Inc. , This is an elegant solution to a long-standing technical issue.
The sale enhances Edwards’ balance sheet flexibility for disciplined investments in technologies for aortic, mitral, tricuspid and pulmonic patients, as well as new therapeutic areas for interventional heartfailure.
Cambridge, MA-based artificial intelligence (AI)-driven health technology company, Anumana, has announced its receipt of the International Organization for Standardization (ISO) 13485 certification for its Quality Management System. ECG-AI LEF, the company’s breakthrough AI algorithm, received U.S.
The same technology that enables a bullet train to travel at speeds up to 200 mph without touching its rails now keeps a failing heart pumping—and in the near future, it will do so via a wireless power connection.
The filing for approval of this product family follows the FDA approval of BioCardia’s Helix biotherapeutic delivery Morph DNA guide system and its Avance transseptal steerable introducer, both of which incorporate Morph DNA technology.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content